{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959122",
  "id": "02959122",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250617",
  "time": "0936",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kth1v75ydb12.pdf",
  "summary": "- **Commercial Manufacturing Agreement signed with SpectronRx for 64Cu-SAR-bisPSMA**  \n- **Production capacity**: Up to 400,000 patient-ready doses annually at Indiana facility (scalable via optional regional US sites)  \n- **Key advantage**: Centralized commercial-scale production with 48-hour shelf-life, enabling nationwide distribution  \n- **Strategic impact**: Complements existing supply agreements, ensuring readiness for commercial rollout post-FDA approval  \n- **Agreement term**: 5 years (effective 17 June 2025) with standard cancellation/extension terms  \n\n*No capital raising, financials, or immediate trading catalysts disclosed.*",
  "usage": {
    "prompt_tokens": 2774,
    "completion_tokens": 133,
    "total_tokens": 2907,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T23:59:31.411887"
}